STERIS plc

(New York Stock Exchange)
Back to all articles
Bullish +75

STERIS stock trades at EUR 197.65 with USD 21.6 billion value

Acquisition AI-generated analysis

πŸ“ˆ STERIS agreed to acquire Xodus Medical for USD 2.10 billion to expand its operating-room consumables portfolio.

πŸ’° The deal is expected to close by December 31, 2026, and will be financed primarily with debt.

πŸ“Š Fiscal first-quarter 2027 results showed adjusted EPS of USD 2.59 and revenue of USD 1.49 billion, up 7.30% year over year.

πŸ” Analysts project Xodus will contribute USD 245 million in revenue and USD 135 million in adjusted EBITDA for calendar year 2026.

πŸ’Έ STERIS expects USD 300 million in cash tax benefits, reducing the effective purchase price to USD 1.80 billion.

πŸ“ˆ Assenagon Asset Management increased its stake by 37.9% to 105,373 shares as of October 19, 2026.

πŸ—“οΈ The company is scheduled to report fiscal second-quarter 2027 results on November 4, 2026.

πŸ’Ή STERIS stock trades at EUR 197.65 in Europe and USD 221.97 in the US with a market cap of USD 21.6 billion.

πŸ“‰ The 52-week trading range for STE is between USD 195.14 and USD 269.44.

Bullish Signals
  • STERIS agreed to acquire Xodus Medical for USD 2.10 billion, a strategic move to expand its operating-room consumables portfolio.
  • Fiscal first-quarter 2027 results beat expectations with adjusted EPS of USD 2.59 and revenue growth of 7.30% year over year.
  • Analysts view the Xodus acquisition as a logical addition to the healthcare business, projecting significant revenue contribution.
  • The company expects USD 300 million in cash tax benefits, effectively lowering the net cost of the acquisition to USD 1.80 billion.
  • Major institutional investor Assenagon increased its stake by 37.9%, signaling strong confidence in the company's trajectory.
Risk Factors
  • The Xodus Medical acquisition will be financed primarily with debt, which may increase leverage and interest obligations.
  • The deal is subject to regulatory approvals and must close by December 31, 2026, introducing execution and timing risks.
Full Analysis
STERIS plc agreed to acquire Xodus Medical for USD 2.10 billion on October 12, 2026, a deal designed to expand its operating-room consumables portfolio. The transaction is expected to close by December 31, 2026, subject to regulatory approvals, and will be financed primarily with debt. Analysts view the acquisition as a logical addition to the company's healthcare business, with projections indicating Xodus could contribute USD 245 million in revenue and USD 135 million in adjusted EBITDA for calendar year 2026. STERIS reported strong fiscal first-quarter 2027 results on August 5, 2026, posting adjusted earnings per share of USD 2.59 and revenue of USD 1.49 billion, representing a 7.30% year-over-year increase. The company is scheduled to report fiscal second-quarter 2027 results on November 4, 2026, with consensus estimates projecting USD 2.68 in earnings per share on USD 1.56 billion in revenue. Additionally, Assenagon Asset Management increased its stake in STERIS by 37.9% to 105,373 shares as of October 19, 2026. STERIS stock trades at EUR 197.65 on the European market and USD 221.97 in the US market as of late October 2026, with a market capitalization of approximately USD 21.6 billion. The company expects to realize USD 300 million in cash tax benefits on a net-present-value basis, effectively reducing the purchase price of Xodus Medical to USD 1.80 billion. Upcoming earnings and the acquisition timeline remain key focal points for investors monitoring the healthcare specialty sector.